CD19 and acute lymphoblastic leukemia: The first-in-human study of tisagenlecleucel, hereafter referred to as anti-CD19 CAR-T cell, was performed in 2010 only in adults with r/r CD19+ B-cell leukaemia and lymphomas (CART19 phase I trial (NCT01029366)), while the first results of its use in two children were published in 2013, showing a complete remission of the B-ALL [8,14].